These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 16393223

  • 1. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study.
    Péron JM, Bureau C, Gonzalez L, Garcia-Ricard F, de Soyres O, Dupuis E, Alric L, Pourrat J, Vinel JP.
    Am J Gastroenterol; 2005 Dec; 100(12):2702-7. PubMed ID: 16393223
    [Abstract] [Full Text] [Related]

  • 2. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P, TAHRS Investigators.
    Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
    [Abstract] [Full Text] [Related]

  • 3. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study.
    Duvoux C, Zanditenas D, Hézode C, Chauvat A, Monin JL, Roudot-Thoraval F, Mallat A, Dhumeaux D.
    Hepatology; 2002 Aug; 36(2):374-80. PubMed ID: 12143045
    [Abstract] [Full Text] [Related]

  • 4. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
    Sharma P, Kumar A, Shrama BC, Sarin SK.
    Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
    [Abstract] [Full Text] [Related]

  • 5. [Successful conservative therapy of hepatorenal syndrome with vasopressin-1-receptor antagonist ornipressin].
    Gülberg V, Luppa P, Pauletzki J, Paumgartner G, Gerbes AL.
    Z Gastroenterol; 1998 Dec; 36(12):1053-8. PubMed ID: 10025057
    [Abstract] [Full Text] [Related]

  • 6. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
    Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J.
    Hepatology; 2002 Oct; 36(4 Pt 1):941-8. PubMed ID: 12297842
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.
    Testro AG, Wongseelashote S, Angus PW, Gow PJ.
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1535-40. PubMed ID: 17784863
    [Abstract] [Full Text] [Related]

  • 8. Terlipressin and albumin combination treatment in hepatorenal syndrome.
    Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, Demir K, Besisik F, Boztas G, Mungan Z, Kaymakoglu S, Okten A.
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccciii-cccv. PubMed ID: 15244209
    [Abstract] [Full Text] [Related]

  • 9. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F, Pantea L, Sniderman K.
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [Abstract] [Full Text] [Related]

  • 10. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice.
    Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, Salmi A, Fagiuoli S, Spadaccini A, Trotta E, Laffi G, Koch M, Riggio O, Boccia S, Felder M, Balzani S, Bruno S, Angeli P, Italian Association of the Hospital Gastroenterologists (AIGO) investigators.
    J Hepatol; 2011 Dec; 55(6):1241-8. PubMed ID: 21703199
    [Abstract] [Full Text] [Related]

  • 11. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
    Skagen C, Einstein M, Lucey MR, Said A.
    J Clin Gastroenterol; 2009 Aug; 43(7):680-5. PubMed ID: 19238094
    [Abstract] [Full Text] [Related]

  • 12. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
    Saner F, Kavuk I, Lang H, Biglarnia R, Frühauf NR, Schäfers RF, Malagó M, Broelsch CE.
    Eur J Med Res; 2004 Feb 27; 9(2):78-82. PubMed ID: 15090293
    [Abstract] [Full Text] [Related]

  • 13. Terlipressin therapy for renal failure in cirrhosis.
    Triantos CK, Samonakis D, Thalheimer U, Cholongitas E, Senzolo M, Marelli L, Leandro G, Patch D, Burroughs AK.
    Eur J Gastroenterol Hepatol; 2010 Apr 27; 22(4):481-6. PubMed ID: 19952764
    [Abstract] [Full Text] [Related]

  • 14. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.
    Gülberg V, Bilzer M, Gerbes AL.
    Hepatology; 1999 Oct 27; 30(4):870-5. PubMed ID: 10498636
    [Abstract] [Full Text] [Related]

  • 15. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
    von Kalckreuth V, Glowa F, Geibler M, Lohse AW, Denzer UW.
    Z Gastroenterol; 2009 Jan 27; 47(1):21-6. PubMed ID: 19156588
    [Abstract] [Full Text] [Related]

  • 16. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail.
    Moreau R, Valla DC, Durand-Zaleski I, Bronowicki JP, Durand F, Chaput JC, Dadamessi I, Silvain C, Bonny C, Oberti F, Gournay J, Lebrec D, Grouin JM, Guémas E, Golly D, Padrazzi B, Tellier Z.
    Liver Int; 2006 Feb 27; 26(1):46-54. PubMed ID: 16420509
    [Abstract] [Full Text] [Related]

  • 17. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial.
    Umgelter A, Reindl W, Wagner KS, Franzen M, Stock K, Schmid RM, Huber W.
    Crit Care; 2008 Feb 27; 12(1):R4. PubMed ID: 18197961
    [Abstract] [Full Text] [Related]

  • 18. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study.
    Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A.
    Hepatology; 2003 Jul 27; 38(1):238-43. PubMed ID: 12830007
    [Abstract] [Full Text] [Related]

  • 19. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A.
    Hepatology; 1999 Jun 27; 29(6):1690-7. PubMed ID: 10347109
    [Abstract] [Full Text] [Related]

  • 20. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.
    Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A.
    J Hepatol; 2007 Oct 27; 47(4):499-505. PubMed ID: 17560680
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.